967
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Is the lack of evidence in older adults with cancer compromising safety?

&
Pages 1059-1061 | Received 18 May 2020, Accepted 31 Jul 2020, Published online: 05 Aug 2020

References

  • Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–2765. .
  • Mohile SG, Xian Y, Dale W, et al. * Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst. 2009;101(17):1206–1215. .
  • Williams GR, Chen Y, Kenzik KM, et al. *Assessment of Sarcopenia Measures, Survival, and Disability in Older Adults Before and After Diagnosis With Cancer. JAMA Network Open. 2020;3(5):e204783. .
  • Rocque GB, Williams GR. Bridging the Data-Free Zone: decision Making for Older Adults With Cancer. J Clin Oncol. 2019;37(36):3469–3471.
  • Scher KS, Hurria A. *Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012;30(17):2036–2038.
  • Williams CP, Kenzik KM, Azuero A, et al. Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast Cancer. Oncologist. 2019;24(1):31–37. .
  • Nightingale G, Skonecki E, Boparai MK. The Impact of Polypharmacy on Patient Outcomes in Older Adults With Cancer. Cancer J. 2017;23(4):211–218.
  • Maggiore RJ, Dale W, Gross CP, et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc. 2014;62(8):1505–1512. .
  • Williams GR, Rier HN, McDonald A, et al. Sarcopenia & aging in cancer. J Geriatr Oncol. 2019 May;10(3):374–377.
  • Levit LA, Singh H, Klepin HD, et al. **Expanding the Evidence Base in Geriatric Oncology: action Items From an FDA-ASCO Workshop. J Natl Cancer Inst. 2018;110(11):1163–1170. .
  • **Oncology Center of Excellence, C.f.D.E.a.R.C., and Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration, Inclusion of Older Adults in Cancer Clinical Trials Guidance for Industry. 2020.
  • U.S. Department of Health and Human Services, F.a.D.A., Oncology Center of Excellence, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies Guidance for Industry. 2019.
  • Williams GR. Geriatric Assessment: precision Medicine for Older Adults With Cancer. J Oncol Pract. 2018;14(2):97–98.
  • Williams GR, Kenzik KM, Parman M, et al. *Integrating geriatric assessment into routine gastrointestinal (GI) consultation: the Cancer and Aging Resilience Evaluation (CARE). J Geriatr Oncol. 2020;11(2):270–273. .
  • Paillaud E, Soubeyran P, Caillet P, et al. *Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey. Eur J Cancer. 2018;103:61–68.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.